<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04948827</url>
  </required_header>
  <id_info>
    <org_study_id>SBP-9330-101</org_study_id>
    <secondary_id>U01DA051077</secondary_id>
    <nct_id>NCT04948827</nct_id>
  </id_info>
  <brief_title>A First-in-Human Study of SBP-9330 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SBP-9330 (With a Nested Food-Effect Arm) After Oral Administration in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Camino Pharma, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanford Burnham Prebys Medical Discovery Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Camino Pharma, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, first-in-human, randomized, double-blind, placebo-controlled,&#xD;
      Single-Ascending Dose (SAD) / Multiple-Ascending Dose (MAD) study incorporating a food-effect&#xD;
      cohort.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Up to 52 days</time_frame>
    <description>Number of drug-related adverse events as determined by clinically significant changes in vital signs, physical examination findings, ECG parameters, C-SSRS questionnaire results, and clinical laboratory results</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SBP-9330: Cmax</measure>
    <time_frame>PK samples will be obtained at selected timepoints from pre-dose until 48 hours post-dose</time_frame>
    <description>Maximum observed concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SBP-9330: Tmax</measure>
    <time_frame>PK samples will be obtained at selected timepoints from pre-dose until 48 hours post-dose</time_frame>
    <description>Time to reach maximum observed concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SBP-9330: AUC 0-24</measure>
    <time_frame>PK samples will be obtained at selected timepoints from pre-dose until 24 hours post-dose</time_frame>
    <description>Area under the concentration time curve from time 0 (dose administration) to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SBP-9330: AUC 0-T</measure>
    <time_frame>PK samples will be obtained at selected timepoints from pre-dose until 48 hours post-dose</time_frame>
    <description>Area under the concentration time curve from time 0 (dose administration) to the time of last quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SBP-9330: AUC 0-∞</measure>
    <time_frame>PK samples will be obtained at selected timepoints from pre-dose until 48 hours post-dose</time_frame>
    <description>Area under the concentration time curve extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SBP-9330: T½</measure>
    <time_frame>PK samples will be obtained at selected timepoints from pre-dose until 48 hours post-dose</time_frame>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SBP-9330: CL/F</measure>
    <time_frame>PK samples will be obtained at selected timepoints from pre-dose until 48 hours post-dose</time_frame>
    <description>Apparent total clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SBP-9330: Vz/F</measure>
    <time_frame>PK samples will be obtained at selected timepoints from pre-dose until 48 hours post-dose</time_frame>
    <description>Apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SBP-9330: C trough</measure>
    <time_frame>PK samples will be obtained at selected timepoints from pre-dose until 48 hours post-dose</time_frame>
    <description>Observed concentration at the end of the dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SBP-9330: Cτ</measure>
    <time_frame>PK samples will be obtained at selected timepoints from pre-dose until 48 hours post-dose</time_frame>
    <description>Concentration at the end of the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SBP-9330: AUCτ</measure>
    <time_frame>PK samples will be obtained at selected timepoints from pre-dose until 48 hours post-dose</time_frame>
    <description>Area under the concentration time curve over the dosing interval at steady state, calculated from 0 to 24 hours (dosing interval)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SBP-9330: T½, eff</measure>
    <time_frame>PK samples will be obtained at selected timepoints from pre-dose until 48 hours post-dose</time_frame>
    <description>Effective half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SBP-9330: CL/Fss</measure>
    <time_frame>PK samples will be obtained at selected timepoints from pre-dose until 48 hours post-dose</time_frame>
    <description>Apparent total clearance at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SBP-9330: Vz/Fss</measure>
    <time_frame>PK samples will be obtained at selected timepoints from pre-dose until 48 hours post-dose</time_frame>
    <description>Apparent volume of distribution at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SBP-9330: RAC(Cmax)</measure>
    <time_frame>PK samples will be obtained at selected timepoints from pre-dose until 48 hours post-dose</time_frame>
    <description>Accumulation ratio evaluated by comparing Day 14 Cmax to Day 1 Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SBP-9330: RAC(AUC)</measure>
    <time_frame>PK samples will be obtained at selected timepoints from pre-dose until 48 hours post-dose</time_frame>
    <description>Accumulation ratio evaluated by comparing Day 14 AUCτ to Day 1 AUC0-24</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Part A - Single-Dose (Active)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each Part A cohort will be randomized to either active SBP-9330 or matching placebo in increasing doses. In each cohort a sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Single-Dose (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each Part A cohort will be randomized to either active SBP-9330 or matching placebo in increasing doses. In each cohort a sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Single-Dose Food-Effect (Active)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this two-period food-effect cohort, each subject will receive the randomly assigned treatment (SBP-9330 or placebo) under fasting conditions (Period 1). After a 7- to 14-day washout period, subjects will receive the same single dose of SBP-9330 or placebo in a fed state (Period 2) 30 minutes after the start of an FDA High-Fat and High-Calorie Breakfast. A sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Single-Dose Food-Effect (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this two-period food-effect cohort, each subject will receive the randomly assigned treatment (SBP-9330 or placebo) under fasting conditions (Period 1). After a 7- to 14-day washout period, subjects will receive the same single dose of SBP-9330 or placebo in a fed state (Period 2) 30 minutes after the start of an FDA High-Fat and High-Calorie Breakfast. A sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SBP-9330 - Multiple-Dose (Active)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each Part B cohort will be randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Multiple-Dose (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each Part B cohort will be randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SBP-9330</intervention_name>
    <description>SBP-9330 oral capsules</description>
    <arm_group_label>Part A - Single-Dose (Active)</arm_group_label>
    <arm_group_label>Part A - Single-Dose Food-Effect (Active)</arm_group_label>
    <arm_group_label>SBP-9330 - Multiple-Dose (Active)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo oral capsules</description>
    <arm_group_label>Part A - Single-Dose (Placebo)</arm_group_label>
    <arm_group_label>Part A - Single-Dose Food-Effect (Placebo)</arm_group_label>
    <arm_group_label>Placebo - Multiple-Dose (Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of written informed consent prior to the initiation of any protocol-specific&#xD;
             procedures&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Healthy male or female subject ≥ 18 and ≤ 55 years of age&#xD;
&#xD;
          4. Body mass index (BMI) ≥ 18.5 kg/m2 and ≤ 32.0 kg/m2&#xD;
&#xD;
          5. Body weight ≥ 50.0 kg at Screening&#xD;
&#xD;
          6. A female subject must meet at least one of the following criteria: a. Is of&#xD;
             childbearing potential and agrees to use an acceptable contraceptive method. b. Is of&#xD;
             non-childbearing potential, defined as surgically sterile (i.e., has undergone&#xD;
             complete hysterectomy, bilateral oophorectomy, or tubal ligation) or is in a&#xD;
             postmenopausal state (i.e., at least 1 year without menses prior to the first study&#xD;
             drug administration without an alternative medical condition and confirmed with a&#xD;
             serum follicle-stimulating hormone [FSH] &gt; 40 IU/L at Screening)&#xD;
&#xD;
          7. Male subjects, if not surgically sterilized, must agree to use adequate contraception&#xD;
             and not donate sperm from the first admission to the CRU until 90 days after the last&#xD;
             study drug administration.&#xD;
&#xD;
          8. Never- or non-smoker (a non-smoker is defined as someone who completely stopped using&#xD;
             nicotine products for at least 2 years prior to the first study drug administration&#xD;
&#xD;
          9. Have no clinically significant medical or mental health conditions captured in the&#xD;
             medical history or evidence of clinically significant findings on the physical&#xD;
             examination and/or ECG, as determined by an Investigator&#xD;
&#xD;
         10. No clinically significant abnormalities in blood pressure, heart rate, body&#xD;
             temperature and respiratory rate and no evidence of orthostatic hypotension or&#xD;
             postural tachycardia at Screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female who is lactating&#xD;
&#xD;
          2. Female who is pregnant according to the pregnancy test at Screening or prior to the&#xD;
             first study drug administration&#xD;
&#xD;
          3. Female who is planning to become pregnant during this study or within 90 days after&#xD;
             the last study drug administration&#xD;
&#xD;
          4. Male with female partner who is pregnant, lactating, or planning to become pregnant&#xD;
             during this study or within 90 days after the last study drug administration&#xD;
&#xD;
          5. Poor venous access as determined by an Investigator at Screening&#xD;
&#xD;
          6. History of significant hypersensitivity to SBP-9330 or any related products (including&#xD;
             excipients of the formulations) as well as severe hypersensitivity reactions (like&#xD;
             angioedema) to any drugs&#xD;
&#xD;
          7. Presence of any medical condition that, in the opinion of an Investigator, poses an&#xD;
             unacceptable risk to the subjects&#xD;
&#xD;
          8. Presence or history of significant gastrointestinal, liver or kidney disease, or&#xD;
             surgery that may affect drug absorption&#xD;
&#xD;
          9. Evidence or history of clinically significant cardiovascular, pulmonary, hematologic,&#xD;
             psychiatric (including mood and substance use disorders), neurological (including&#xD;
             migraines, seizures, and epilepsy), endocrine, renal, hepatic, gastrointestinal,&#xD;
             immunologic or dermatologic disease&#xD;
&#xD;
         10. History of malignancy within the past five years, except for successfully treated&#xD;
             basal cell carcinoma of the skin&#xD;
&#xD;
         11. History of suicidal ideation or suicidal behavior as per the C-SSRS questionnaire&#xD;
             administered at Screening&#xD;
&#xD;
         12. Evidence or history of significant psychiatric disease or any DSM-5 disorder as&#xD;
             assessed by the Mini International Neuropsychiatric Interview (M.I.N.I.) administered&#xD;
             at Screening&#xD;
&#xD;
         13. Routine or chronic use of more than three grams of acetaminophen daily&#xD;
&#xD;
         14. Strenuous activity, sunbathing, and contact sports within 48 hours prior to (first)&#xD;
             admission to the CRU&#xD;
&#xD;
         15. Current alcohol consumption exceeding two standard drinks per day on average (1&#xD;
             standard drink=10 grams of alcohol) for male subjects and one standard drink per day&#xD;
             on average for female subjects&#xD;
&#xD;
         16. History of alcohol or drug (other than caffeine) use disorder within 12 months prior&#xD;
             to Screening&#xD;
&#xD;
         17. Any clinically significant illness in the 28 days prior to the first study drug&#xD;
             administration&#xD;
&#xD;
         18. QTcF interval (QT interval corrected for heart rate according to Fridericia) &gt; 450 ms&#xD;
             for males and &gt; 470 ms for females at Screening or on Day -1&#xD;
&#xD;
         19. Positive test result for alcohol and/or drugs of abuse at Screening or prior to the&#xD;
             first drug administration&#xD;
&#xD;
         20. Positive test results for HIV-1/HIV-2 antibodies, hepatitis B surface antigen or&#xD;
             hepatitis C antibody&#xD;
&#xD;
         21. Consumption of any prescription drugs (with the exception of hormonal contraceptives&#xD;
             or hormone replacement therapy) or over-the-counter medications and nutrients known to&#xD;
             modulate cytochrome P450 (CYP450) enzymes activity (e.g., grapefruit or grapefruit&#xD;
             juice, pomelo juice, star fruit, or Seville [blood] orange products) or St. John's&#xD;
             Wort within 14 days prior to the first study drug administration&#xD;
&#xD;
         22. Consumption of other prescription and over-the-counter medication not specifically&#xD;
             excluded by Exclusion Criterion 21 including health supplements and herbal remedies&#xD;
             within 7 days prior to the first study drug administration (an exception is made for&#xD;
             paracetamol [acetaminophen], which is allowed up to admission to the clinic).&#xD;
&#xD;
         23. Any other clinically significant abnormalities in laboratory test results at Screening&#xD;
             that would, in the opinion of an Investigator, increase the subject's risk of&#xD;
             participation, jeopardize complete participation in the study, or compromise&#xD;
             interpretation of study data&#xD;
&#xD;
         24. Intake of an investigational product in the 30 days or 5 half-lives (whichever is&#xD;
             longer) prior to Screening&#xD;
&#xD;
         25. Inclusion in a previous cohort of this clinical study&#xD;
&#xD;
         26. Employee of the contract research organization (CRO) or the Sponsor.&#xD;
&#xD;
         27. Blood donation (excluding plasma donation) of approximately 500 mL within 56 days&#xD;
             prior to Screening&#xD;
&#xD;
         28. Plasma donation within 7 days prior to Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vijay Hingorani, MD, PhD</last_name>
    <phone>858-864-8124</phone>
    <email>clinicaltrials@caminopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Altasciences Clinical Kansas, Inc</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>913-696-1601</phone>
      <email>regulatory@altasciences.com</email>
    </contact>
    <investigator>
      <last_name>Martin Kankam, MD, PhD, MPH, FAPCR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

